Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Equity Ratio data on file, last reported at 0.9 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio fell 3.37% year-over-year to 0.9; the trailing twelve-month figure through Dec 2025 stood at 0.9 (down 3.37% YoY), and the FY2025 full-year result was 0.9, down 3.37% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.9, down from 0.95 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.97 in Q2 2021 and bottomed at 0.9 in Q4 2025.
• The 5-year median for Equity Ratio is 0.93 (2022), against an average of 0.93.
• The widest annual swing landed in 2021, when Equity Ratio jumped 334.82%; it then slipped 5.08% in 2022.
• A 5-year view of Equity Ratio shows it stood at 0.95 in 2021, then decreased by 5.08% to 0.9 in 2022, then slipped by 0.72% to 0.9 in 2023, then grew by 3.36% to 0.93 in 2024, then decreased by 3.37% to 0.9 in 2025.
• The last three Equity Ratio figures came in at 0.9 (Q4 2025), 0.95 (Q3 2025), and 0.93 (Q2 2025), per Business Quant data.

Peer Comparison